Amphastar Pharmaceuticals, Inc.

Fundamentals6.0
Price Action3.0
News Sentiment4.0
AI Rating
4.0

Key Drivers

  • Strong Cash Generation
  • Margin Compression
  • Moderate Leverage

AI
AI Summary

4.0

AMPH should be viewed less as a straightforward cheap cash generator and more as a business whose investment case now hinges on whether it can stabilize rebate pressure and reverse sharp margin compression before the lower-quality profit profile becomes permanent, even though strong free cash flow, liquidity, and buybacks still provide downside support.

MarginCompression
FreeCashFlow‍
RebatePressure

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Strong Cash Generation
  • Margin Compression
  • Moderate Leverage

AMPH posted strong full-year 2025 profitability and cash flow with solid liquidity, but recent quarterly margin compression and moderate leverage temper the outlook.

CashFlow
Leverage

Price Behavior

3.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Weak support
  • Oversold bounce

AMPH is in a clear short-term downtrend, with lower highs/lows and failed rebounds, leaving only a possible oversold bounce from the $17-$18 support zone.

bearish
oversold
Support Level: $17.00-$18.00
Resistance Level: $18.50-$19.00

Sharp drop from a recent last month high on 2026-05-07 to a new period low signals a sudden momentum breakdown

Sentiment & News

4.0

Key News Insights:

  • EPS Miss
  • BAQSIMI Pressure
  • Revenue Outlook

Amphastar's Q1 results were mixed, with revenue holding up but adjusted EPS missing estimates amid ongoing BAQSIMI rebate and discount pressure, even as management kept its full-year revenue outlook intact.

Earnings
BAQSIMI

The earnings miss and product-specific pricing pressure may weigh on sentiment, though reaffirmed revenue guidance helps limit downside